Bladder Cancer Weekly

December 02, 2024

Videos

Peer-to-Peer Clinical Conversations

Trimodality Therapy Preserves Bladder in High-Grade T1 Bladder Cancer Patients - Douglas Dahl

Douglas Dahl

Douglas Dahl discusses a Phase II trial of trimodality therapy for T1 high-grade bladder cancer, recently published in the Journal of Clinical Oncology.

View

NIAGARA Trial Shows Durvalumab Plus Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer - Thomas Powles

Thomas Powles

Thomas Powles joins Zachary Klaassen to discuss the NIAGARA trial results.

View

Beyond the Abstracts

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract

Modulation of the Tumor Microenvironment in Non-Muscle-Invasive Bladder Cancer by OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: Effects on Tumor-Associated Macrophages, Tumor-Infiltrating Lymphocytes, and Monoamine Oxidases - Beyond the Abstract

Conference Coverage

SCS AUA 2024: Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

SCS AUA 2024: Bladder Cancer Recurrence Analysis in Veterans and Outcomes (BRAVO): White Light Versus Blue Light Cystoscopy Outcomes Among NMIBC Patients in an Equal Access Setting

ESMO 2024: Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: Conditional Survival and Long-Term Safety in Patients Treated for ≥1 or ≥2 Years in JAVELIN Bladder 100

ESMO 2024: Phase 2 Study of Futibatinib plus Pembrolizumab in Patients with Advanced/Metastatic Urothelial Carcinoma: Final Analysis of Efficacy and Safety

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Use of Multiparametric and Biparametric Magnetic Resonance Imaging in Bladder Cancer Staging: Prospective Observational Study and Analysis of Radiologist Learning Curve.

Rationale of restaging transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer in the current era.

Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs - Beyond the Abstract

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.

Cohort Profile: VZNKUL-NMIBC Quality Indicators Program: A Flemish Prospective Cohort to Evaluate the Quality Indicators in the Treatment of Non-Muscle-Invasive Bladder Cancer.

Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.

Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.

Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment.

Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials.

Efficacy of Inpatient, Evidence-Based Tobacco Use Treatment of Patients With Bladder Cancer After Radical Cystectomy.

Penoscrotal Extension and Fistulation From Urothelial Carcinoma of the Bladder

Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies.

State of the Art: The Microbiome in Bladder Cancer.

French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC).

French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC).

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login